NHS sets aside £340m for new Innovative Medicines FundNHS England has matched its financial backing of the Cancer Drugs Fund (CDF) with an equivalent pot of Share XNHS sets aside £340m for new Innovative Medicines Fundhttps://pharmaphorum.com/news/nhs-sets-aside-340m-for-new-innovative-medicines-fund/
BioNTech grows in cell therapies, buying Kite’s TCR platformBioNTech has found a use for some of the windfall cash it has raked in from its COVID-19 Share XBioNTech grows in cell therapies, buying Kite’s TCR platformhttps://pharmaphorum.com/news/biontech-grows-in-cell-therapies-buying-kites-tcr-platform/
Health Innovators – Jo Brewer, AdaptimmuneIn this episode of Health Innovators, pharmaphorum founder Paul Tunnah interviews Jo Brewer, senior vice president of allogeneic Share XHealth Innovators – Jo Brewer, Adaptimmunehttps://pharmaphorum.com/video/health-innovators-jo-brewer-adaptimmune/
Gilead combs Shoreline for NK cell therapies in $2.3bn allianceGilead Sciences’ cell therapy Kite Pharma has bulked up its position in natural killer (NK) cell therapies, pledging Share XGilead combs Shoreline for NK cell therapies in $2.3bn alliancehttps://pharmaphorum.com/news/gilead-combs-shoreline-for-nk-cell-therapies-in-2-3bn-alliance/
Bayer’s two-pronged cell/gene therapy assault on Parkinson’s enters clinicBayer subsidiary BlueRock Therapeutics has dosed the first Parkinson’s disease patient in a phase 1 trial of its Share XBayer’s two-pronged cell/gene therapy assault on Parkinson’s enters clinichttps://pharmaphorum.com/news/bayers-two-pronged-cell-gene-therapy-assault-on-parkinsons-enters-clinic/
New Cell & Gene Therapy Collective seeks to boost UK adoptionThe UK has been a global leader in introducing cell and gene therapies that can potentially transform the Share XNew Cell & Gene Therapy Collective seeks to boost UK adoptionhttps://pharmaphorum.com/views-and-analysis/new-cell-gene-therapy-collective-seeks-to-boost-uk-adoption/
Tackling diabetes & ALS with cell therapyIsraeli company Kadimastem is developing regenerative medicine therapies based on differentiated cells derived from human embryonic stem cells Share XTackling diabetes & ALS with cell therapyhttps://pharmaphorum.com/views-and-analysis/tackling-diabetes-als-with-cell-therapy/
Collaboration is key to advancing cell therapy researchDr. Anne Kerber, VP, Head of Clinical Development, Europe at Kite, a Gilead Company, explains how the company Share XCollaboration is key to advancing cell therapy researchhttps://pharmaphorum.com/r-d/collaboration-is-key-to-advancing-cell-therapy-research/
Big data and cell therapy development: the pharmaphorum podcastIn the latest episode of the podcast pharmaphorum’s website editor Catherine Longworth speaks with Dr Darrin Disley, who’s the Share XBig data and cell therapy development: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/mogrify-big-data-cell-therapy
